Dadha Pharma Distribution Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 8.12 M
as on 24-10-2024
- Company Age 9 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 20.00 Cr
as on 24-10-2024
- Revenue 23.25%
(FY 2023)
- Profit -78.09%
(FY 2023)
- Ebitda -50.79%
(FY 2023)
- Net Worth 7.44%
(FY 2023)
- Total Assets 8.50%
(FY 2023)
About Dadha Pharma Distribution
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.12 M.
The company has closed loans amounting to ₹20.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mohanchand Dadha, Jethusingh Bhati, and Advait Pandit serve as directors at the Company.
- CIN/LLPIN
U74900TN2015PLC102202
- Company No.
102202
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Sep 2015
- Date of AGM
23 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dadha Pharma Distribution?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohanchand Dadha  | Director | 15-Sep-2015 | Current |
| Jethusingh Bhati | Whole-Time Director | 09-Oct-2015 | Current |
| Advait Pandit | Director | 21-Jan-2021 | Current |
Financial Performance and Corporate Structure Insights of Dadha Pharma Distribution.
Dadha Pharma Distribution Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 23.25% increase. The company also saw a substantial fall in profitability, with a 78.09% decrease in profit. The company's net worth moved up by a moderate rise of 7.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dadha Pharma Distribution?
In 2022, Dadha Pharma Distribution had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Netmeds Healthcare LimitedActive 14 years 3 monthsMohanchand Dadha, Jethusingh Bhati and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 22 Feb 2016 | ₹20.00 Cr | Satisfied |
How Many Employees Work at Dadha Pharma Distribution?
Dadha Pharma Distribution has a workforce of 33 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dadha Pharma Distribution, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dadha Pharma Distribution's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
